Beclin1、LC3和mTOR在肝癌中的表达及临床意义

目的 通过检测Beclin1、LC3和雷帕霉素靶蛋白(mTOR)在肝癌组织中的表达,并结合各相关临床病理指标,从而探讨Beclin1、LC3和mTOR的表达水平在肝癌发生发展中的作用及其相互之间的关系.方法 采用免疫组织化学技术,检测56例肝癌组织和40例正常肝脏组织中Beclin1、LC3和mTOR蛋白的表达情况,并分析二者与肝癌各相关临床病理特征之间的关系.结果 Beclin1、LC3和mTOR蛋白在肝癌组织中的阳性表达率分别为75％、70％和50％,均明显高于正常肝组织中的阳性表达率25％、30％、28％,差异有统计学意义(P<0.05).Beclin1与LC3在肝癌中表达呈正相关(r=0.643,P<0.01),与mTOR表达之间无明显相关性(r=-0.167,P>0.05).LC3与mTOR表达呈负相关(r=-0.386,P<0.01).Beclin1、LC3和mTOR的表达均与年龄、性别、肿瘤大小、HBSAg、AFP值等均无显著相关性(P>0.05),但与病理学分级和有无胆管癌栓有关(P<0.05).结论 Beclin1、LC3和mTOR的异常高表达可能与肝癌的发生关系密切.

Expression and clinical significance of Beclin1,LC3 and mTOR in hepatic carcinoma

Objective To investigate the expression of Beclin1 ,LC3 and mTOR protein in hepatic carcinoma,and study their correla-tions to the clinicopathologic characteristics.To explore the effect of Beclin1 ,LC3 and mTOR protein expression in the occurrence,de-velopment of hepatic carcinoma and their interrelation.Methods The expression of Beclin1 ,LC3 and mTOR protein in 56 cases of he-patic carcinoma,40 cases of normal liver tissues were detected by immunohistochemistry.At the same time,to investigate the relativity and clinicopathologic characteristics of expression of Beclin1 ,LC3 and mTOR in hepatic carcinoma.Results The positive expression rate of Beclin1 ,LC3and mTOR in hepatic carcinoma was significantly higher than normal liver tissues,with significant difference (P <0.05).The expression of Beclin1 was positively correlated with LC3 (r =0.643,P <0.01 )and was not associated with mTOR(r =-0.167,P >0.05),and the expression of LC3 was negatively correlated with mTOR in hepatic carcinoma(r =-0.386,P <0.01 ). The expression of Beclin1 ,LC3 and mTOR showed no obvious correlations with the age,gender,tumor size,HBSAg and serous alpha-fe-toprotein (AFP)(P >0.05),but were correlated with pathological grading and biliary tumor thrombi (P <0.05).Conclusion The abnormal expression of Beclin1 ,LC3 and mTOR are closely associated with the occurrence and development of hepatic carcinoma.